• Je něco špatně v tomto záznamu ?

Influence of Surgical Excision on the Survival of Patients With Stage 4 High-Risk Neuroblastoma: A Report From the HR-NBL1/SIOPEN Study

K. Holmes, U. Pötschger, ADJ. Pearson, S. Sarnacki, G. Cecchetto, J. Gomez-Chacon, R. Squire, E. Freud, A. Bysiek, LE. Matthyssens, M. Metzelder, T. Monclair, J. Stenman, M. Rygl, L. Rasmussen, JM. Joseph, S. Irtan, S. Avanzini, J. Godzinski, K....

. 2020 ; 38 (25) : 2902-2915. [pub] 20200708

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc21012213

Grantová podpora
8177 Cancer Research UK - United Kingdom

PURPOSE: To evaluate the impact of surgeon-assessed extent of primary tumor resection on local progression and survival in patients in the International Society of Pediatric Oncology Europe Neuroblastoma Group High-Risk Neuroblastoma 1 trial. PATIENTS AND METHODS: Patients recruited between 2002 and 2015 with stage 4 disease > 1 year or stage 4/4S with MYCN amplification < 1 year who had completed induction without progression, achieved response criteria for high-dose therapy (HDT), and had no resection before induction were included. Data were collected on the extent of primary tumor excision, severe operative complications, and outcome. RESULTS: A total of 1,531 patients were included (median observation time, 6.1 years). Surgeon-assessed extent of resection included complete macroscopic excision (CME) in 1,172 patients (77%) and incomplete macroscopic resection (IME) in 359 (23%). Surgical mortality was 7 (0.46%) of 1,531. Severe operative complications occurred in 142 patients (9.7%), and nephrectomy was performed in 124 (8.8%). Five-year event-free survival (EFS) ± SE (0.40 ± 0.01) and overall survival (OS; 0.45 ± 0.02) were significantly higher with CME compared with IME (5-year EFS, 0.33 ± 0.03; 5-year OS, 0.37 ± 0.03; P < .001 and P = .004). The cumulative incidence of local progression (CILP) was significantly lower after CME (0.17 ± 0.01) compared with IME (0.30 ± 0.02; P < .001). With immunotherapy, outcomes were still superior with CME versus IME (5-year EFS, 0.47 ± 0.02 v 0.39 ± 0.04; P = .038); CILP was 0.14 ± 0.01 after CME and 0.27 ± 0.03 after IME (P < .002). A hazard ratio of 1.3 for EFS associated with IME compared with CME was observed before and after the introduction of immunotherapy (P = .030 and P = .038). CONCLUSION: In patients with stage 4 high-risk neuroblastoma who have responded to induction therapy, CME of the primary tumor is associated with improved survival and local control after HDT, local radiotherapy (21 Gy), and immunotherapy.

Agia Sofia Children's Hospital Athens Greece

Children's Cancer Research Institute Department of Paediatrics Medical University of Vienna Vienna Austria

Department of Gastrointestinal and Paediatric Surgery Princess Elisabeth Children's Hospital Ghent University Hospital Ghent Belgium

Department of Paediatric Haematology and Oncology Princess Elisabeth Children's Hospital Ghent University Hospital Ghent Belgium

Department of Paediatric Surgery Marciniak Hospital and Department of Paediatric Traumatology and Emergency Medicine Wroclaw Medical University Wroclaw Poland

Department of Pediatric Surgery Necker Enfants Malades Hospital Assistance Publique Hôpitaux de Paris University de Paris Paris France

Department of Pediatric Surgery University Children's Hospital Kraków Poland

Department of Surgical Gastroenterology A Odense University Hospital Odense Denmark

Institut Gustave Roussy Villejuif Paris France

Institute of Cancer Research and Royal Marsden Hospital Sutton United Kingdom

Jagiellonian University Medical College Kraków Poland

Karolinska University Hospital Stockholm Sweden

Oslo University Hospital Rikshospitalet Oslo Norway

Paediatric Haematology Oncology Our Lady's Children's Hospital Crumlin Dublin Republic of Ireland

Paediatric Oncology Fondazione IRCCS Istituto Nazionale dei Tumori Milan Italy

Paediatric Oncology Great Ormond Street Hospital London United Kingdom

Paediatric Oncology Leeds Teaching Hospital Leeds United Kingdom

Paediatric Oncology Paediatric Surgical Oncology Unit Hospital Universitario La FE Valencia Spain

Paediatric Surgery Medical University of Vienna Vienna Austria

Paediatric Surgery St George's Hospital London and Royal Marsden Hospital Sutton United Kingdom

Pediatric Surgery Department of Women's and Children's Health University of Padua Padua Italy

Pediatric Surgery Unit IRCCS Istituto Giannina Gaslini Genoa Italy

Portuguese Institute of Oncology Lisbon Portugal

Sackler School of Medicine Tel Aviv University Tel Aviv Israel

Schneider Children's Medical Center of Israel Petach Tikvah Israel

Sorbonne University Department of Visceral and Neonatal Pediatric Surgery Armand Trousseau Hospital Assistance Publique Hôpitaux de Paris Paris France

St Anna Children's Hospital and Children's Cancer Research Institute Department of Paediatrics Medical University of Vienna Vienna Austria

Sydney Children's Hospital Randwick New South Wales Australia

University College Hospital London United Kingdom

University Hospital Lausanne Lausanne Switzerland

University Hospital Motol Prague Czech Republic

University Hospital of Aarhus Aarhus Denmark

University of Oslo Oslo Norway

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21012213
003      
CZ-PrNML
005      
20210507103124.0
007      
ta
008      
210420s2020 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1200/JCO.19.03117 $2 doi
035    __
$a (PubMed)32639845
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Holmes, Keith $u Paediatric Surgery, St George's Hospital London and Royal Marsden Hospital, Sutton, United Kingdom
245    10
$a Influence of Surgical Excision on the Survival of Patients With Stage 4 High-Risk Neuroblastoma: A Report From the HR-NBL1/SIOPEN Study / $c K. Holmes, U. Pötschger, ADJ. Pearson, S. Sarnacki, G. Cecchetto, J. Gomez-Chacon, R. Squire, E. Freud, A. Bysiek, LE. Matthyssens, M. Metzelder, T. Monclair, J. Stenman, M. Rygl, L. Rasmussen, JM. Joseph, S. Irtan, S. Avanzini, J. Godzinski, K. Björnland, M. Elliott, R. Luksch, V. Castel, S. Ash, W. Balwierz, G. Laureys, E. Ruud, V. Papadakis, J. Malis, C. Owens, H. Schroeder, M. Beck-Popovic, T. Trahair, A. Forjaz de Lacerda, PF. Ambros, MN. Gaze, K. McHugh, D. Valteau-Couanet, RL. Ladenstein, International Society of Paediatric Oncology Europe Neuroblastoma Group (SIOPEN)
520    9_
$a PURPOSE: To evaluate the impact of surgeon-assessed extent of primary tumor resection on local progression and survival in patients in the International Society of Pediatric Oncology Europe Neuroblastoma Group High-Risk Neuroblastoma 1 trial. PATIENTS AND METHODS: Patients recruited between 2002 and 2015 with stage 4 disease > 1 year or stage 4/4S with MYCN amplification < 1 year who had completed induction without progression, achieved response criteria for high-dose therapy (HDT), and had no resection before induction were included. Data were collected on the extent of primary tumor excision, severe operative complications, and outcome. RESULTS: A total of 1,531 patients were included (median observation time, 6.1 years). Surgeon-assessed extent of resection included complete macroscopic excision (CME) in 1,172 patients (77%) and incomplete macroscopic resection (IME) in 359 (23%). Surgical mortality was 7 (0.46%) of 1,531. Severe operative complications occurred in 142 patients (9.7%), and nephrectomy was performed in 124 (8.8%). Five-year event-free survival (EFS) ± SE (0.40 ± 0.01) and overall survival (OS; 0.45 ± 0.02) were significantly higher with CME compared with IME (5-year EFS, 0.33 ± 0.03; 5-year OS, 0.37 ± 0.03; P < .001 and P = .004). The cumulative incidence of local progression (CILP) was significantly lower after CME (0.17 ± 0.01) compared with IME (0.30 ± 0.02; P < .001). With immunotherapy, outcomes were still superior with CME versus IME (5-year EFS, 0.47 ± 0.02 v 0.39 ± 0.04; P = .038); CILP was 0.14 ± 0.01 after CME and 0.27 ± 0.03 after IME (P < .002). A hazard ratio of 1.3 for EFS associated with IME compared with CME was observed before and after the introduction of immunotherapy (P = .030 and P = .038). CONCLUSION: In patients with stage 4 high-risk neuroblastoma who have responded to induction therapy, CME of the primary tumor is associated with improved survival and local control after HDT, local radiotherapy (21 Gy), and immunotherapy.
650    _2
$a mladiství $7 D000293
650    _2
$a protokoly protinádorové kombinované chemoterapie $x terapeutické užití $7 D000971
650    _2
$a dítě $7 D002648
650    _2
$a předškolní dítě $7 D002675
650    _2
$a cytoredukční chirurgie $x škodlivé účinky $x metody $x statistika a číselné údaje $7 D065426
650    _2
$a přežití bez známek nemoci $7 D018572
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a kojenec $7 D007223
650    _2
$a novorozenec $7 D007231
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a multicentrické studie jako téma $7 D015337
650    _2
$a staging nádorů $7 D009367
650    _2
$a neuroblastom $x mortalita $x patologie $x chirurgie $x terapie $7 D009447
650    _2
$a proporcionální rizikové modely $7 D016016
650    _2
$a randomizované kontrolované studie jako téma $7 D016032
650    _2
$a výsledek terapie $7 D016896
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Pötschger, Ulrike $u Children's Cancer Research Institute, Department of Paediatrics, Medical University of Vienna, Vienna, Austria
700    1_
$a Pearson, Andrew D J $u Institute of Cancer Research and Royal Marsden Hospital, Sutton, United Kingdom
700    1_
$a Sarnacki, Sabine $u Department of Pediatric Surgery, Necker Enfants-Malades Hospital, Assistance Publique Hôpitaux de Paris, University de Paris, Paris, France
700    1_
$a Cecchetto, Giovanni $u Pediatric Surgery, Department of Women's and Children's Health, University of Padua, Padua, Italy
700    1_
$a Gomez-Chacon, Javier $u Paediatric Oncology, Paediatric Surgical Oncology Unit, Hospital Universitario La FE, Valencia, Spain
700    1_
$a Squire, Roly $u Paediatric Oncology, Leeds Teaching Hospital, Leeds, United Kingdom
700    1_
$a Freud, Enrique $u Schneider Children's Medical Center of Israel, Petach, Tikvah, Israel $u Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
700    1_
$a Bysiek, Adam $u Department of Pediatric Surgery, University Children's Hospital, Kraków, Poland
700    1_
$a Matthyssens, Lucas E $u Department of Gastrointestinal and Paediatric Surgery, Princess Elisabeth Children's Hospital, Ghent University Hospital, Ghent, Belgium
700    1_
$a Metzelder, Martin $u Paediatric Surgery, Medical University of Vienna, Vienna, Austria
700    1_
$a Monclair, Tom $u Oslo University Hospital Rikshospitalet, Oslo, Norway
700    1_
$a Stenman, Jakob $u Karolinska University Hospital, Stockholm, Sweden
700    1_
$a Rygl, Michal $u University Hospital Motol, Prague, Czech Republic
700    1_
$a Rasmussen, Lars $u Department of Surgical Gastroenterology A, Odense University Hospital, Odense, Denmark
700    1_
$a Joseph, Jean-Marc $u University Hospital Lausanne, Lausanne, Switzerland
700    1_
$a Irtan, Sabine $u Sorbonne University, Department of Visceral and Neonatal Pediatric Surgery, Armand Trousseau Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France
700    1_
$a Avanzini, Stefano $u Pediatric Surgery Unit, IRCCS Istituto Giannina Gaslini, Genoa, Italy
700    1_
$a Godzinski, Jan $u Department of Paediatric Surgery, Marciniak Hospital, and Department of Paediatric Traumatology and Emergency Medicine, Wroclaw Medical University, Wroclaw, Poland
700    1_
$a Björnland, Kristin $u Oslo University Hospital Rikshospitalet, Oslo, Norway $u University of Oslo, Oslo, Norway
700    1_
$a Elliott, Martin $u Paediatric Oncology, Leeds Teaching Hospital, Leeds, United Kingdom
700    1_
$a Luksch, Roberto $u Paediatric Oncology, Fondazione IRCCS, Istituto Nazionale dei Tumori, Milan, Italy
700    1_
$a Castel, Victoria $u Paediatric Oncology, Paediatric Surgical Oncology Unit, Hospital Universitario La FE, Valencia, Spain
700    1_
$a Ash, Shifra $u Schneider Children's Medical Center of Israel, Petach, Tikvah, Israel
700    1_
$a Balwierz, Walentyna $u Jagiellonian University Medical College, Kraków, Poland
700    1_
$a Laureys, Geneviève $u Department of Paediatric Haematology and Oncology, Princess Elisabeth Children's Hospital, Ghent University Hospital, Ghent, Belgium
700    1_
$a Ruud, Ellen $u Oslo University Hospital Rikshospitalet, Oslo, Norway $u University of Oslo, Oslo, Norway
700    1_
$a Papadakis, Vassilios $u Agia Sofia Children's Hospital, Athens, Greece
700    1_
$a Malis, Josef $u University Hospital Motol, Prague, Czech Republic
700    1_
$a Owens, Cormac $u Paediatric Haematology/Oncology, Our Lady's Children's Hospital, Crumlin, Dublin, Republic of Ireland
700    1_
$a Schroeder, Henrik $u University Hospital of Aarhus, Aarhus, Denmark
700    1_
$a Beck-Popovic, Maja $u University Hospital Lausanne, Lausanne, Switzerland
700    1_
$a Trahair, Toby $u Sydney Children's Hospital, Randwick, New South Wales, Australia
700    1_
$a Forjaz de Lacerda, Ana $u Portuguese Institute of Oncology, Lisbon, Portugal
700    1_
$a Ambros, Peter F $u Children's Cancer Research Institute, Department of Paediatrics, Medical University of Vienna, Vienna, Austria
700    1_
$a Gaze, Mark N $u University College Hospital, London, United Kingdom
700    1_
$a McHugh, Kieran $u Paediatric Oncology, Great Ormond Street Hospital, London, United Kingdom
700    1_
$a Valteau-Couanet, Dominique $u Institut Gustave Roussy, Villejuif, Paris, France
700    1_
$a Ladenstein, Ruth Lydia $u St Anna Children's Hospital and Children's Cancer Research Institute, Department of Paediatrics, Medical University of Vienna, Vienna, Austria
710    2_
$a International Society of Paediatric Oncology Europe Neuroblastoma Group (SIOPEN)
773    0_
$w MED00002596 $t Journal of clinical oncology : official journal of the American Society of Clinical Oncology $x 1527-7755 $g Roč. 38, č. 25 (2020), s. 2902-2915
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32639845 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20210420 $b ABA008
991    __
$a 20210507103122 $b ABA008
999    __
$a ok $b bmc $g 1650562 $s 1132592
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 38 $c 25 $d 2902-2915 $e 20200708 $i 1527-7755 $m Journal of clinical oncology $n J. clin. Oncol. $x MED00002596
GRA    __
$a 8177 $p Cancer Research UK $2 United Kingdom
LZP    __
$a Pubmed-20210420

Najít záznam

Citační ukazatele

Možnosti archivace